Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

The premium of a big pharma license deal

This is a preview of subscription content, access via your institution

Relevant articles

Open Access articles citing this article.

Access options

Buy article

Get time limited or full article access on ReadCube.

$32.00

All prices are NET prices.

Figure 1: Big pharma pays more than SMEs in upfront payments when in-licensing.

References

  1. Goodman, M. Nat. Rev. Drug Discov. 8, 443 (2009).

    Article  CAS  Google Scholar 

  2. Frei, P. & Leleux, B. Nat. Biotechnol. 22, 1049–1051 (2004).

    CAS  PubMed  Google Scholar 

  3. Frei, P. & Dev, K.K. Drug Discov. Today 18, 1027–1029 (2013).

    Article  Google Scholar 

Download references

Author information

Authors and Affiliations

Authors

Corresponding authors

Correspondence to Patrik Frei or Kumlesh K Dev.

Ethics declarations

Competing interests

P.F. is CEO of Venture Valuation, Zurich, Switzerland.

Rights and permissions

Reprints and Permissions

About this article

Verify currency and authenticity via CrossMark

Cite this article

O'Connell, K., Frei, P. & Dev, K. The premium of a big pharma license deal. Nat Biotechnol 32, 617–619 (2014). https://doi.org/10.1038/nbt.2946

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/nbt.2946

This article is cited by

Search

Quick links

Nature Briefing

Sign up for the Nature Briefing newsletter — what matters in science, free to your inbox daily.

Get the most important science stories of the day, free in your inbox. Sign up for Nature Briefing